Assaf Berger1, Kenneth Bernstein2, Juan Diego Alzate2, Reed Mullen2, Joshua S Silverman3, Erik P Sulman3, Bernadine R Donahue3, Anna C Pavlick4, Jason Gurewitz4, Monica Mureb5, Janice Mehnert4, Kathleen Madden4, Amy Palermo2, Jeffrey S Weber4, John G Golfinos2, Douglas Kondziolka2. 1. Department of Neurological Surgery, Center for Advanced Radiosurgery, NYU Langone Health Medical Center, New York University, 530 First Avenue, New York, NY, 10016, USA. assaf.berger@gmail.com. 2. Department of Neurological Surgery, Center for Advanced Radiosurgery, NYU Langone Health Medical Center, New York University, 530 First Avenue, New York, NY, 10016, USA. 3. Department of Radiation Oncology, NYU Langone Health Medical Center, New York University, New York, USA. 4. Medical Oncology, Perlmutter Cancer Center, NYU Langone Health Medical Center, New York University, New York, USA. 5. Department of Neurosurgery, Westchester Medical Center, Valhalla, USA.
Abstract
PURPOSE: New therapies for melanoma have been associated with increasing survival expectations, as opposed to the dismal outcomes of only a decade ago. Using a prospective registry, we aimed to define current survival goals for melanoma patients with brain metastases (BM), based on state-of-the-art multimodality care. METHODS: We reviewed 171 melanoma patients with BM receiving stereotactic radiosurgery (SRS) who were followed with point-of-care data collection between 2012 and 2020. Clinical, molecular and imaging data were collected, including systemic treatment and radiosurgical parameters. RESULTS: Mean age was 63 ± 15 years, 39% were female and 29% had BRAF-mutated tumors. Median overall survival after radiosurgery was 15.7 months (95% Confidence Interval 11.4-27.7) and 25 months in patients managed since 2015. Thirty-two patients survived [Formula: see text] 5 years from their initial SRS. BRAF mutation-targeted therapies showed a survival advantage in comparison to chemotherapy (p = 0.009), but not to immunotherapy (p = 0.09). In a multivariable analysis, both immunotherapy and the number of metastases at 1st SRS were predictors of long-term survival ([Formula: see text] 5 years) from initial SRS (p = 0.023 and p = 0.018, respectively). Five patients (16%) of the long-term survivors required no active treatment for [Formula: see text] 5 years. CONCLUSION: Long-term survival in patients with melanoma BM is achievable in the current era of SRS combined with immunotherapies. For those alive [Formula: see text] 5 years after first SRS, 16% had been also off systemic or local brain therapy for over 5 years. Given late recurrences of melanoma, caution is warranted, however prolonged survival off active treatment in a subset of our patients raises the potential for cure.
PURPOSE: New therapies for melanoma have been associated with increasing survival expectations, as opposed to the dismal outcomes of only a decade ago. Using a prospective registry, we aimed to define current survival goals for melanoma patients with brain metastases (BM), based on state-of-the-art multimodality care. METHODS: We reviewed 171 melanoma patients with BM receiving stereotactic radiosurgery (SRS) who were followed with point-of-care data collection between 2012 and 2020. Clinical, molecular and imaging data were collected, including systemic treatment and radiosurgical parameters. RESULTS: Mean age was 63 ± 15 years, 39% were female and 29% had BRAF-mutated tumors. Median overall survival after radiosurgery was 15.7 months (95% Confidence Interval 11.4-27.7) and 25 months in patients managed since 2015. Thirty-two patients survived [Formula: see text] 5 years from their initial SRS. BRAF mutation-targeted therapies showed a survival advantage in comparison to chemotherapy (p = 0.009), but not to immunotherapy (p = 0.09). In a multivariable analysis, both immunotherapy and the number of metastases at 1st SRS were predictors of long-term survival ([Formula: see text] 5 years) from initial SRS (p = 0.023 and p = 0.018, respectively). Five patients (16%) of the long-term survivors required no active treatment for [Formula: see text] 5 years. CONCLUSION: Long-term survival in patients with melanoma BM is achievable in the current era of SRS combined with immunotherapies. For those alive [Formula: see text] 5 years after first SRS, 16% had been also off systemic or local brain therapy for over 5 years. Given late recurrences of melanoma, caution is warranted, however prolonged survival off active treatment in a subset of our patients raises the potential for cure.
Authors: Wolfram E Samlowski; Gordon A Watson; Michael Wang; Ganesh Rao; Paul Klimo; Kenneth Boucher; Dennis C Shrieve; Randy L Jensen Journal: Cancer Date: 2007-05-01 Impact factor: 6.860
Authors: Peter E Fecci; Cosette D Champion; Jacob Hoj; Courtney M McKernan; C Rory Goodwin; John P Kirkpatrick; Carey K Anders; Ann Marie Pendergast; John H Sampson Journal: Clin Cancer Res Date: 2019-06-18 Impact factor: 12.531
Authors: Ugur Selek; Eric L Chang; Samuel J Hassenbusch; Almon S Shiu; Frederick F Lang; Pamela Allen; Jeffrey Weinberg; Raymond Sawaya; Moshe H Maor Journal: Int J Radiat Oncol Biol Phys Date: 2004-07-15 Impact factor: 7.038
Authors: Michael J Moravan; Peter E Fecci; Carey K Anders; Jeffrey M Clarke; April K S Salama; Justus D Adamson; Scott R Floyd; Jordan A Torok; Joseph K Salama; John H Sampson; Paul W Sperduto; John P Kirkpatrick Journal: Cancer Date: 2020-01-23 Impact factor: 6.860